Inhibitory effects of icotinib combined with antiangiogenic drugs in human non ‐small cell lung cancer xenograft models are better than single target drugs

ConclusionsIcotinib combined with bevacizumab or rh-endostatin has a stronger inhibitory effect on tumor growth than single-target drug in vivo, with no additional side effects.

Source: Thoracic Cancer - December 2, 2021 Category: Cancer & Oncology Authors: Peng Jiang, Yan Zhang, Jiadong Cui, Xiuxiu Wang, Yu Li Tags: ORIGINAL ARTICLE Source Type: research